# NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

> **NCT07683325** · PHASE2 · RECRUITING · sponsor: **Agomab Spain S.L.U.** · enrollment: 320 (estimated)

## Conditions studied

- Fibrostenotic Crohn's Disease

## Interventions

- **DRUG:** Ontunisertib
- **DRUG:** Ontunisertib
- **DRUG:** Ontunisertib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07683325
- **Lead sponsor:** Agomab Spain S.L.U.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-30
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-06-30
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683325, "NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07683325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*